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Abstract Here, we summarise the current clinical
knowledge on Ara h 6 sensitisation and clinical rele-
vance of this sensitisation pattern using five illustrative
clinical cases. The literature search yielded a total of
166 papers, and an additional relevant article was found
by ‘snowballing’. A total of ten articles were considered
relevant for this review. Most studies included patients
with a sensitisation to Ara h 6 and cosensitisation to
Ara h 2. Only three studies showed patients with a
mono-sensitisation to Ara h 6. This illustrates that Ara
h 6 mono-sensitisation has been neglected in literature.
We present a case series of five children with sensitisa-
tion to peanut component Ara h 6. Only one of these
five patients showed Ara h 8 cosensitivity. Three out of
the five children had a positive double-blind placebo-
controlled food challenge (DBPCFC), with moderate to
strong reactions.
Conclusion: A mono-sensitisation to peanut component
Ara h 6 is uncommon but can cause severe allergic reactions.
Therefore, the determination of sIgE to Ara h 6 is warranted in
patients with a suspected peanut allergy, especially in the ab-
sence of sensitisation to Ara h 1, 2, 3 and 9.
What is known:
• Peanut allergy is common and can cause severe allergic reactions.
• The diagnostics of peanut allergy has recently improved with the use of
component resolved diagnosis
What is new:
• A mono-sensitisation to peanut component Ara h 6 is uncommon, but
can cause severe allergic reactions
• Determination of sIgE to Ara h 6 is warranted in patients with a
suspected peanut allergy, especially in the absence of sensitisation to
Ara h 1, 2, 3 and 9
Keywords Ara h 6 . Components . Double-blind
placebo-controlled food challenge (DBPCFC) . Peanut allergy
Abbreviations
Ara h Arachis hypogaea
CRD Component-resolved diagnosis
DBPCFC Double-blind placebo-controlled food challenge
IUIS International Union of Immunological Societies
LTP Lipid transfer protein
PBS Phosphate-buffered saline
PR-10 Pathogenesis-related class 10
sIgE Specific IgE
SPT Skin prick test
Introduction
Peanut allergy is common and can cause severe allergic reac-
tions. Even a tiny amount of peanut allergen can induce aller-
gic reactions, including anaphylaxis. The majority of peanut-
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allergic patients remain allergic to peanuts for the rest of their
lives [3]. Diagnosis is traditionally based on the clinical his-
tory, sensitisation (skin prick test (SPT) and/or specific IgE
(sIgE) and optionally, a double-blind placebo-controlled food
challenge (DBPCFC) test [26].
The diagnostics of peanut allergy has recently improved
with the use of component-resolved diagnosis (CRD). CRD
measures sIgE against individual allergens utilising purified or
recombinant allergens. The ImmunoCAP ISAC is an ad-
vanced method that detects sIgE for most individual peanut
components [9]. More than 13 peanut components have been
identified and accepted by the Allergen Nomenclature
Subcommittee of the International Union of Immunological
Societies (IUIS). The most important and clinically relevant
components are Arachis Hypogaea (Ara h) 1, 2, 3, 6, 8 and 9.
Ara h 1, 2 and 3 are seed storage proteins that can induce
severe allergic reactions. sIgE to Ara h 2 is the best predictor
for a clinically relevant peanut allergy and has high diagnostic
accuracy in comparison to other components [14]. Ara h 8 is a
pathogenesis-related class 10 (PR-10) protein homologous to
the Bet v 1 allergen component of birch pollen and is involved
in the cross-sensitisation between pollen and peanut. Allergic
reactions due to this cross-reactive protein usually remain lim-
ited to oral allergy symptoms. Anaphylaxis due to Ara h 8 has
been described only in exceptional cases [11]. Sensitisation to
Ara h 9, a lipid transfer protein (LTP), is in most cases accom-
panied by sensitisation to Ara h 1, 2 and 3[23]. Ara h 9 is a
clinically relevant allergen in peanut-allergic patients around
the Mediterranean [17, 19].
This systematic review focuses on the clinical relevance
and severity of sensitisation to component Ara h 6, a 2S albu-
min, a conglutin [16]. Little attention is paid in the literature to
Ara h 6 in contrast to Ara h 2 sensitisation, which has been
investigated far more extensively and, hence, is now generally
recognised as predictor for clinically relevant peanut allergy
[12, 21, 22]. However, Ara h 6 and Ara h 2 are both 2S
albumin storage proteins and approximately 60 % homolo-
gous. Ara h 6 and Ara h 2 are comparable in molecular size,
amino acid sequence and structure [6, 13, 15, 20].
In this study, we summarise the current clinical knowledge
on Ara h 6 sensitisation and describe five relevant cases with
four out of five cases showing mono-sensitisation to Ara h 6.
We measured clinical relevance of sensitisation to Ara h 6 by
performing DBPCFCs.
Method
Data sources and literature search
Our search was performed in line with the methods and proce-
dures of the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines for reporting this
systematic review, excluding irrelevant items. The registration
number in PROSPERO is CRD42015020451. We used Ovid
MEDLINE, EMBASE, Cochrane, Web-of-science, Scopus and
Google scholar databases to identify relevant articles by using
strings shown in Table 1. We only included studies in English,
and there was no restriction on publication date. Mouse models
and animal studies were excluded. Initially, all articles on Ara h
6 and Ara h 2 were included because studies on a mono-
sensitisation toAra h 6were not available. Subsequently, in vitro
studies, biochemical studies, studies using skin prick tests with
Ara h 2 and/or Ara h 6 extracts only and studies on dermatitis
were excluded. Nine of 166 articles identified in our initial da-
tabase search and one article found by ‘snowballing’ were con-
sidered relevant for this systematic review. The literature screen-
ing was performed by one author, and the included studies were
checked by a second author. This literature selection procedure
is shown schematically in Fig. 1.
This review comprises a retrospective cases series of five
children with sensitisation to component Ara h 6. These pa-
tients were selected from the clinical practice of the
Department of Allergology, Erasmus MC in Rotterdam and
the Department of Paediatric Allergology, Renier de Graaf
Group (RdGG) in Delft, the Netherlands, between 2012 and
2015. Sensitisation to peanut was measured by both SPT and
sIgE. Peanut components Ara h 1, 2, 3, 6, 8 and 9 were mea-
sured, and finally, clinical relevance was evaluated by
performing a peanut DBPCFC test.
A SPT with peanut extract was performed by applying a
drop of the allergen extract on the skin of the volar aspect of
the forearm. The extract was pierced through the skin barrier
with a lancet. The SPTs were performed with peanut extracts,
generated as previously described by de Jong et al. [8]. A
dilution buffer was used as negative control, and histamine
(1 %) was used as positive control. A mean diameter ≥3 mm
was considered as positive [8]. For the SPT extracts, the pea-
nuts (raw, not roasted, unsalted organic nuts) were
homogenised mechanically, ground with a mortar and pestle,
defatted by ether extraction, and subsequently air-dried. This
pretreated material was stored at −20 °C until needed for fur-
ther preparation. The pretreated peanut was defrosted regular-
ly, and a 10 % (w/v) extract in phosphate-buffered saline (PBS
pH 7.4, containing 0.03 % human serum albumin and 0.5 %
phenol) was made. For use in SPT, the extract was defrosted
an hour before the skin test and mixed [8].
The Immulite 2000 XPi system (Siemens) was used to
determine sIgE to peanut extract, based on the principle of
solid-phase, two-step and chemilumuniscent immunoassay.
A value of >0.35 IE/L is considered as positive. The
ImmunoCAP ISAC provided sIgE results for 112 components
from more than 51 allergens simultaneously, using only 30-
mL serum, and was used to determine sIgE to Ara h 1,2,3,6,8
and 9. The micro-array ISAC 112 (ThermoFisher, Uppsala,
Sweden) is a solid-phase fluoro- immunoassay that detects
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specific IgE antibodies to the proteins fixed on ISAC surface.
The technique was performed following the manufacturer’s
instructions [9]. The results were measured in ISAC
Standardized Units (ISU-E). Values <0.3 are considered neg-
ative, 0.3–0.9 are considered as low, 1–14.9 as moderate to
high and ≥15 as very high.
Each patient underwent a DBPCFCwith masked food con-
taining the suspected allergen in an increasing dose at time
intervals of 30 min. Placebo and active challenges were ran-
domly administered on separate days with at least a 1-week
interval. Blinding was ensured for the physician, the nurse and
the patient, and blinding was broken 24 h after the challenge.
The validated and standardised food challenge material used
in the DBPCFC was prepared according to the recipe devel-
oped by Berber-Vlieg et al. in 2008[27]. Flour of roasted pea-
nuts were used and the food matrix predominantly consisted
of wheat, sugar, gingerbread spice mix and coconut. The food
challenge test consisted of a six-step incremental doses re-
gime. Upon completion of the challenge test, the child had
consumed 1.75, 3.5, 14, 70, 130 and 350 mg protein,
Table 1 Search stings used to identify relevant articles
Embase (((ara OR nara ORmara) AND ((h2 AND h6) OR (h-2 AND h-6) OR ‘h 2 6’OR ‘h2 6’)) OR (arah2AND arah6) OR (arah-2
AND arah-6) OR arah2-6 OR arah-2-6):ab,ti
PubMed (((ara[tiab] OR nara[tiab] OR mara[tiab]) AND ((h2[tiab] AND h6[tiab]) OR (h-2[tiab] AND h-6[tiab]) OR h-2-6[tiab] OR
h2-6[tiab])) OR (arah2[tiab] AND arah6[tiab]) OR (arah-2[tiab] AND arah-6[tiab]) OR arah2-6[tiab] OR arah-2-6[tiab])
Cochrane (((ara OR nara ORmara) AND ((h2 AND h6) OR (h-2 AND h-6) OR ‘h 2 6’OR ‘h2 6’)) OR (arah2AND arah6) OR (arah-2
AND arah-6) OR arah2-6 OR arah-2-6):ab,ti
Web-of-science TS= ((((ara OR nara ORmara) AND ((h2ANDh6) OR (h-2 AND h-6) OR Bh 2 6^OR Bh2 6^)) OR (arah2AND arah6) OR
(arah-2 AND arah-6) OR arah2-6 OR arah-2-6) )
Scopus TITLE-ABS-KEY((((ara OR nara OR mara) AND ((h2 AND h6) OR (h-2 AND h-6) OR Bh 2 6^ OR Bh2 6^)) OR (arah2
AND arah6) OR (arah-2 AND arah-6) OR arah2-6 OR arah-2-6) )
Google scholar Bara h 6^ Bara h 2^
Records idenfied through database 
searching
(n = 166  )
gnineercS
In
cl
ud
ed
El
ig
ib
ili
ty
noitacifitnedI
Records aer duplicates removed
(n = 161  )
Records screened
(n =19)
Records excluded
(n = 142)
Full-text arcles assessed for eligibility
(n = 10)
Full-text arcles excluded, with 
reasons
(n = 0)
Studies included in qualitave 
synthesis
(n = 10)
Addional records idenfied through 
other sources (‘snowballing’)
(n = 1  )
Fig. 1 Summary of the search
and selection
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equivalent to three peanuts in total. The DBPCFC test was
discontinued and considered positive when (1) objective
symptoms occurred, or when (2) subjective symptoms re-
occurred twice after the same dose of challenge material had
been administered, three times consecutively, or (3) when se-
vere subjective symptoms persisted for more than an hour.
Placebo reactions were assed according to a protocol previ-
ously described by Vlieg-Boertsra et al. [28]. If the child pre-
sented with the same symptoms on the placebo as on the
verum day, the DBPCFC test was considered as
undetermined.
Relevant clinical papers
The ten relevant clinical studies on Ara h 6 mono-sensitisation
or Ara h 6 with cosensitisations are summarised here and
presented in Table 2.
The first study by Peeters et al. included 30 peanut allergic
patients [25]. The aim of this study was to investigate whether
sensitisation to individual allergens Ara h 1, Ara h 2, Ara h 3
and Ara h 6 measured with immunoblots was correlated with
clinical severity. Twenty-two patients (73.3 %)were sensitised
to Ara h 6 and Ara h 2. There was no Ara h 6 mono-
sensitisation observed. The authors concluded that Ara h 2
and Ara h 6 appeared to be the most potent allergens and that
sensitisation to these components is indicative for severe al-
lergic reactions.
The study by Flinterman et al. measured the sIgE reactivity
with immunoblots to major peanut allergens in 20 peanut-
allergic patients [10]. A sensitisation to Ara h 2 and Ara h 6
was observed in 16 patients (80 %). None of the patients had a
mono-sensitisation to Ara h 6. This study concluded that Ara h
2 and Ara h 6 were the most frequently recognised major
peanut allergens in this study.
The study by Codreanu et al. demonstrated a sensitisation
to Ara h 2 and Ara h 6 measured with ImmunoCAP in 149 of
the in total 166 peanut-allergic patients (89.7 %) [7]. Ara h 6
mono-sensitisation was observed in three patients (1.8 %).
The cases series published by Asarnoj et al. demonstrated
one patient with a sensitisation to Ara h 6 and Ara h 8 mea-
sured with ImmunoCAP [4]. This patient developed a grade II
anaphylaxis during a food challenge test.
A study with 107 peanut-allergic patients was performed
by Klemans et al. [13]. The aim of this study was to assess the
diagnostic value of sIgE to Ara h 6. This study showed 48
patients (44.8 %) sensitised to Ara h 2 and Ara h 6 and 4
patients (3.7 %) mono-sensitised to Ara h 6 measured with
ImmunoCAP ISAC. The authors concluded that the diagnos-
tic value of sIgE to Ara h 6 on the population level was as
good as sIgE to Ara h 2.
Kukkonen et al. performed a study in 102 children with a
peanut-sensitisation or a high suspicion of peanut allergy [18].
Peanut components to Ara h 1, 2, 3, 6, 8 and 9 sIgE was
measured with ImmunoCAP ISAC, and a food challenge test
was performed. There was no specification as to how many
patients were sensitised for the different components.
However, they concluded that Ara h 2 and Ara h 6 sensitisa-
tion was associated with severe reactions.
The study by Ballmer-Weber et al. included 68 children
and adults with a positive DBPCFC peanut or a history of
peanut allergy [5]. Of these 68 peanut allergic patients, 50
patients were sensitised to Ara h 2 and Ara h 6 measured with
ImmunoCAP. Mono-sensitisation to Ara h 6 was not demon-
strated. Therefore, the authors concluded that Ara h 6 appears
not to be an essential component in the diagnostics of peanut
allergy.
The study by Agbriel et al. aimed to evaluate peanut CRD
as a diagnostic and prognostic method in 117 children [2].
Seventy-four patients (64 %) were sensitised to Ara h 6 mea-
sured with ImmunoCAP ISAC (64 %). The conclusion of this
study was that sensitisation to Ara h 6 and Ara h 2 were shown
to be the best predictors of peanut allergy in their study
population.
Ackerbauer et al. performed a study on 65 peanut allergic
patients [1]. Sensitisation patterns against peanut allergens
Ara h 1, 2, 3, 6, 8 and 9 were measured with ImmunoCAP
ISAC. Forty-six patients (70.7 %) were sensitised to Ara h 2
and Ara h 6. The authors concluded that the majority of symp-
tomatic peanut-allergic patients were sensitised to Ara h 2 and/
or Ara h 6.
Finally, Pedrosa et al. studied 22 children with a history of
peanut allergy and a positive SPT and positive sIgE peanut.
The authors demonstrated with ImmunoCAP ISAC that 13
children were sensitised to Ara h 2 and Ara h 6 and 4 were
mono-sensitised to Ara h 6. The conclusion of this study was
that the measurement of sIgE to Ara h 2 in combination with
Ara h 6 improves the diagnosis of peanut allergy [24].
Case series
Below, we describe the case studies for the five individual
children. The results of SPT peanut, sIgE peanut and peanut
components Ara h 1, 2, 3, 6, 8 and 9 and the outcome of
DBPCFCs with peanut of the five children are summarised
in Table 3.
Patient 1
A 9-year-old atopic boy was referred to the Erasmus MC’s
Department of Allergology because of his cow’s milk allergy.
He also showed a peanut and tree nut sensitisation. sIgE to
peanut was positive (2.1 IE/L), and the SPT with peanut ex-
tract was positive (13 mm). He never consumed peanuts. A
DBPCFC peanut was subsequently performed. During the
challenge, he experienced no symptoms during the placebo
day. On the verum day, he had mild oral itch after each
Eur J Pediatr
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incremental dose, which disappeared quickly and did not
worsen during the test. After the last dose he had some ab-
dominal pain. About 4 h after the last part, the symptoms
worsened and he developed extensive urticarial skin lesions,
associated with abdominal pain. These symptoms disappeared
several hours after anti-histamine treatment. ImmunoCAP
ISAC revealed a sensitisation to peanut component Ara h 6
(11.2 ISU-E). In addition, Ara h 8 sensitivity was observed
(3.3 ISU-E), most likely caused by cross-sensitisation due to
primary Bet v 1 (PR-10) sensitisation (56 ISU-E). The
DBPCFC was judged as positive and the patient was advised
to avoid peanuts.
Patient 2
A 15-year-old boy was referred to the Department of
Paediatric Allergology RdGG for his peanut allergy. He had
experienced a severe anaphylactic reaction after the consump-
tion of peanuts at the age of 10. The symptoms included an-
gioedema of the lips and tongue, hoarseness and vomiting.
sIgE to peanut was positive (5.8 IE/L), and the SPT with
peanut extract showed a positive result (15 mm).
ImmunoCAP ISAC demonstrated an Ara h 6 mono-
sensitisation (7.83 ISU-E). The DBPCFC showed no symp-
toms on the placebo day. On the verum day, after step 3, the
patient complained of an itching mouth. Step 3 was repeated
and gives no problems, but after step 5, the patient experi-
enced severe persistent abdominal pain for more than an hour
and tiredness. The DBPCFC was terminated prematurely, and
the patient was treated with anti-histamine, which reduced the
symptoms slightly. Once home, the boy experienced a head-
ache and felt tired. The DBPCFC was judged as positive, and
the patient was advised to avoid peanuts.
Patient 3
A 9-year-old boy was referred to RdGG’s Department of
Paediatric Allergology for his allergies. This boy had
experienced an allergic reaction after consumption of peanuts
at the age of 3 and 5. The allergic reaction at both ages includ-
ed a swollen and sore throat, difficulty with breathing and
angioedema of the eyes. SPT with peanut extract and sIgE
peanut were both positive (8 mm and 4.1 IE/L, respectively).
In ImmunoCAP ISAC, a mono-sensitisation was measured to
component Ara h 6 (2.32 ISU-E). A DBPCFCwas performed:
the patient showed mild symptoms on the placebo day and
milder symptoms on the verum day. The DBPCFC was
judged as negative, and the boy was allowed to introduce
peanut in his diet.
Patient 4
A 13-year-old boy was referred to the Department of
Paediatric Allergology, RdGG, proved to be sensitised to tree
nuts and peanuts with unknown clinical relevance. SPT with
peanut was positive (7 mm), and sIgE to peanut was also
positive (14.0 IE/L). ImmunoCAP ISAC demonstrated an
Ara h 6 mono-sensitisation (0.58 ISU-E). A DBPCFC was
performed. The boy showed no symptoms on the placebo
day, but after step 3 on the verum day, he experienced severe
subjective symptoms as nausea, abdominal pain and listless
behaviour for more than an hour. These symptoms disap-
peared after treatment with anti-histamine and the boy was
sent home asymptomatic. The DBPCFC was judged as posi-
tive and the patient was advised to avoid peanuts.
Patient 5
A 7-year-old boy was referred to Erasmus MC’s Department
of Allergology because of his food allergies. Hewas sensitised
to peanut with unknown clinical relevance. SPT with peanut
extract and sIgE to peanut were both positive (9 mm and
6.1 IE/L, respectively). ImmunoCAP ISAC measured a
mono-sensitisation to component Ara h 6 (2.23 ISU-E). A
DBPCFC was performed and judged as negative, and there-
fore, the child was allowed to introduce peanuts to his diet.
Table 3 SPT peanut (mm), sIgE
peanut (IE/L), ISAC peanut
components (ISU/E) and
DBPCFC peanut results
Patient 1 2 3 4 5
SPT peanut 13 15 8 7 9
sIgE peanut 2.1 5.8 4.1 14.0 6.1
Ara h 1 Neg Neg Neg Neg Neg
Ara h 2 Neg Neg Neg Neg Neg
Ara h 3 Neg Neg Neg Neg Neg
Ara h 6 11.2 7.83 2.32 0.58 2.23
Ara h 8 3,3 Neg Neg Neg Neg
Ara h 9 Neg Neg Neg Neg Neg
DBPCFC Urticarial skin lesions,
abdominal pain
Itching mouth,
abdominal pain,
headache
Neg Nausea and
abdominal pain,
listless behaviour
Neg
Eur J Pediatr
Discussion
Our literature search demonstrated that there is little informa-
tion available on Ara h 6 mono-sensitisation. Therefore, the
importance of Ara h 6 sensitisation is difficult to define. Three
studies on peanut allergy demonstrated patients with mono-
sensitisation. However, studies selected for this review dem-
onstrated that Ara h 2 and Ara h 6 were the most frequently
recognised major peanut allergens [1, 10].
Our series of relatively unique cases confirms that patients
with a mono-sensitisation to peanut component Ara h 6 do
indeed exist. Moreover, this mono-sensitisation may cause
moderate to severe allergic reactions. Three out of five chil-
dren showed a clinically relevant Ara h 6 mono-sensitisation,
confirmed by a DBPCFC. These reactions consisted of exten-
sive urticarial skin lesions, headaches, persisting abdominal
pain and nausea. In a case report by Asarnoj et al., a severe
allergic reaction (anaphylaxis) due to predominant Ara h 6
sensitisation was described; however, the patient was also
sensitised to Ara h 8[4]. This was also the case for patient 1
in our cases series. This patient was also sensitised to Ara h 8,
most probably due to primary Bet v 1 (PR-10) sensitisation.
As a result, this patient is officially not mono-sensitised to Ara
h 6. However, Ara h 8 is not a peanut storage protein family
member, and we consider Ara h 8 to be sensitisation with mild
clinical relevance. In the context of primary sensitisation to
peanut storage proteins, we consider this patient to be mono-
sensitised to Ara h 6.
Although Ara h 6 sensitisation may apparently cause mod-
erate to severe allergic reactions, it is hardly recognised in
clinical practice. The lack of readily available test systems
for sIgE against Ara h 6, in addition to the relatively expensive
and unique ImmunoCAP ISAC system, probably contributes
to this. However, an overlooked Ara h 6 mono-sensitisation
may cause harmful situations during a food challenge or pea-
nut introduction at home. Therefore, the importance of the Ara
h 6 sIgE determination should not be underestimated. In re-
cent years, most researchers have focused on the Ara h 2
peanut component and found that sensitisation is highly pre-
dictive of a severe clinical peanut allergy. In addition to Ara h
2, Ara h 6 sensitisation coexists in many peanut-allergic pa-
tients [13]; however, mono-sensitisation to Ara h 6 also exists,
as this study clearly demonstrates. This warrants increased
attention being paid to patients with Ara h 6 mono-
sensitisation.
Conclusion
A mono-sensitisation to peanut component Ara h 6 is uncom-
mon, but in some cases clinically relevant as it can cause
severe allergic reactions, including anaphylaxis. Therefore,
the determination of sIgE to Ara h 6 is warranted in patients
with a suspected peanut allergy, especially in the absence of
sensitisation to Ara h 1, 2, 3 and 9.
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